证券代码：600479 证券简称：千金药业 公告编号：2025-044 株洲千金药业股份有限公司 2025 年半年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 报告期内，中药材及饮片生产板块营业收入较上年同期下降 47.91%，营业成本较上年同期下降 46.20%，主要是由于药材市场竞 争及波动影响所致； | | | | | 营业 | 营业 | | | --- | --- | --- | --- | --- | --- | --- | | | | | | 收入 | 成本 | 毛利率 | | | | | 毛利 | 比上 | 比上 | 比上年 | | 分行业 | 营业收入 | 营业成本 | 率（%） | 年同 | 年同 | 同期增 | | | | | | 期增 | 期增 | 减（%） | | | | | | 减（%） | 减（%） | | | 药品生 产 | 1,002,314,561.98 | 320,812,474.13 | 67.99 | 7.20 | 7.21 | 持平 | | 中药材 | | | | ...

证券代码：600479 证券简称：千金药业 公告编号：2025-043 株洲千金药业股份有限公司 株洲千金药业股份有限公司（以下简称"公司"）拟通过发行股份及支付现 金方式购买湖南千金湘江药业股份有限公司 28.92%的股权及湖南千金协力药业 有限公司 68.00%的股权（以下简称"本次交易"）。 上海证券交易所并购重组审核委员会（以下简称"上交所重组委"）于 2025 年 8 月 18 日召开 2025 年第 12 次并购重组审核委员会审议会议，对公司本次交 易的申请进行了审议。根据上交所重组委发布的《上海证券交易所并购重组审核 委员会 2025 年第 12 次审议会议结果公告》，本次会议的审议结果为：本次交易 符合重组条件和信息披露要求。 本次交易尚需经中国证券监督管理委员会同意注册后方可实施。本次交易能 否取得注册，以及取得注册的时间均存在不确定性，公司将根据审核进展情况及 时履行信息披露义务，敬请广大投资者关注后续公告并注意相关投资风险。 特此公告。 株洲千金药业股份有限公司 2025 年 8 月 20 日 1 关于发行股份及支付现金购买资产暨关联交易事项获得上 海证券交易所并购重组审核委员会审核通过 ...

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received approval from the restructuring committee for its share issuance to acquire assets, which is expected to enhance its control over subsidiaries and strengthen management [1][5]. Group 1: Transaction Details - The transaction involves issuing shares to acquire a total of 28.92% equity in Qianjin Xiangjiang Pharmaceutical and 68.00% equity in Qianjin Xieli Pharmaceutical [2][3]. - The total transaction price for the acquired assets is 62,346.69 million yuan, with 362.54 million yuan paid in cash and 61,984.15 million yuan through share issuance [4][5]. - The share issuance price is set at 8.77 yuan per share, which is 80% of the average trading price over the previous 120 trading days [2][5]. Group 2: Valuation and Financial Impact - The valuation reports indicate that the equity of Qianjin Xiangjiang Pharmaceutical is assessed at 124,670.00 million yuan, reflecting an increase of 87.77% from its book value, while Qianjin Xieli Pharmaceutical is valued at 38,671.00 million yuan, showing a 73.28% increase [3][4]. - After the transaction, Qianjin Pharmaceutical's total share capital will increase to 494,674,584 shares, with the controlling shareholder, Zhuzhou Guotou, increasing its direct holding to 34.11% [5][6]. Group 3: Strategic Implications - The acquisition will enhance Qianjin Pharmaceutical's control over its subsidiaries, increasing its stake in Qianjin Xiangjiang Pharmaceutical to 79.92% and 100% in Qianjin Xieli Pharmaceutical [5]. - This move is expected to facilitate better management and coordination within the company, aligning with its strategic plan of "one main and two auxiliary" [5].

Core Viewpoint - The Shanghai Stock Exchange's M&A Review Committee approved Qianjin Pharmaceutical's asset acquisition plan, indicating compliance with restructuring conditions and information disclosure requirements [1] Group 1: Transaction Details - Qianjin Pharmaceutical plans to acquire a 28.92% stake in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and a 68% stake in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. [1] Group 2: Review Committee Requirements - The review committee requested the company to explain the basis and rationale for the projected gross margin levels of the main products during the forecast period, considering the impact of drug procurement and historical gross margin changes [1] - The committee also required the company to detail how the transaction will enhance product resource integration and the value of drug registration certificates, as well as the adequacy of information disclosure regarding the integration and management arrangements for the acquired companies [1]

Core Viewpoint - Qianjin Pharmaceutical (600479) is set to undergo a significant asset acquisition review on August 18, aiming to enhance its Western medicine segment through the purchase of stakes in Qianjin Xiangjiang Pharmaceutical and Qianjin Xieli Pharmaceutical, despite facing challenges such as declining profits and sales prices in its target companies [1][3][5]. Group 1: Acquisition Details - Qianjin Pharmaceutical plans to acquire 28.92% of Qianjin Xiangjiang Pharmaceutical and 68% of Qianjin Xieli Pharmaceutical, with a total transaction value of 623 million yuan [3][8]. - Post-acquisition, Qianjin Pharmaceutical's stake in Qianjin Xiangjiang will increase to 79.92%, achieving 100% control over Qianjin Xieli [3][4]. - The acquisition aims to address the mismatch between capital investment and returns from the target companies, thereby improving profitability [3][6]. Group 2: Financial Performance of Target Companies - Qianjin Xiangjiang Pharmaceutical reported revenues of 640 million yuan and 704 million yuan for 2023 and 2024, with net profits of 105 million yuan and 106 million yuan respectively [6]. - Qianjin Xieli Pharmaceutical's revenues for the same period were 232 million yuan and 248 million yuan, with net profits declining from 39.16 million yuan to 23.84 million yuan [6]. - The decline in Qianjin Xieli's net profit is attributed to increased R&D investments in new heart and liver drugs [6][7]. Group 3: Market Challenges - Qianjin Xiangjiang's key product, Valsartan capsules, experienced price drops of 14.65% and 18.52% in 2023 and 2024, respectively, alongside declines in other major products [7][8]. - The pharmaceutical market is facing overall price reductions due to various factors, including national drug price negotiations and the expiration of patents [7][8]. - Experts suggest that the acquisition committee will focus on the ongoing profitability of the target assets during the review [7][8]. Group 4: Valuation and Payment Structure - The acquisition involves a mix of cash and stock payments, with the share issuance price set at 8.41 yuan per share, representing a discount compared to the market price of 10.9 yuan [8][9]. - The valuation of Qianjin Xiangjiang and Qianjin Xieli shows significant premiums, with respective increases of 87.77% and 73.28% over their book values [10].

Core Viewpoint - Qianjin Pharmaceutical is set to undergo a significant asset acquisition review on August 18, aiming to enhance its western medicine segment through the purchase of stakes in Qianjin Xiangjiang Pharmaceutical and Qianjin Xieli Pharmaceutical, despite facing challenges such as declining profits and sales prices in its target companies [1][3][6]. Group 1: Acquisition Details - Qianjin Pharmaceutical plans to acquire 28.92% of Qianjin Xiangjiang Pharmaceutical and 68% of Qianjin Xieli Pharmaceutical, with a total transaction value of 623 million yuan [3][8]. - Post-acquisition, Qianjin Pharmaceutical's stake in Qianjin Xiangjiang will increase to 79.92%, and it will gain 100% control over Qianjin Xieli [3][4]. - The acquisition aims to address the mismatch between capital investment and returns in the target companies, thereby improving profitability [3][4]. Group 2: Financial Performance of Target Companies - Qianjin Xieli Pharmaceutical is projected to see a decline in net profit in 2024, while Qianjin Xiangjiang has experienced a drop in sales prices for its main products [1][6]. - Financial data indicates that Qianjin Xiangjiang's revenue for 2023 and 2024 was 640 million yuan and 704 million yuan, with net profits of 105 million yuan and 106 million yuan, respectively [6]. - Qianjin Xieli's revenue for the same period was 232 million yuan and 248 million yuan, with net profits of approximately 39 million yuan and 24 million yuan [6]. Group 3: Market Challenges - Both target companies face risks from declining drug prices and sales volumes, influenced by national pricing policies and market dynamics [7][6]. - Qianjin Xiangjiang's key product, Valsartan capsules, saw price drops of 14.65% and 18.52% in 2023 and 2024, respectively [7]. - The overall drug market is experiencing price declines due to various factors, including patent expirations and increased competition [7]. Group 4: Valuation and Payment Structure - The acquisition involves a mix of cash and stock payments, with the issuance price set at 8.41 yuan per share, representing a discount compared to the current market price of 10.9 yuan [8][9]. - The valuation of Qianjin Xiangjiang's equity is estimated at 1.247 billion yuan, reflecting an increase of 87.77% from its book value, while Qianjin Xieli's equity is valued at 387 million yuan, up 73.28% [10].

Core Viewpoint - The company, Zhuzhou Qianjin Pharmaceutical Co., Ltd., plans to acquire 28.92% equity in Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68.00% equity in Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of issuing shares and cash payment, pending approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [1][2]. Group 1 - The company’s board of directors guarantees that the announcement contains no false records, misleading statements, or major omissions, and they bear individual and joint responsibility for the authenticity, accuracy, and completeness of the content [1]. - The Shanghai Stock Exchange's M&A Review Committee is scheduled to hold its 12th review meeting on August 18, 2025, to review the company's application for this transaction [1]. - The transaction is subject to approval by the Shanghai Stock Exchange and registration with the China Securities Regulatory Commission, with uncertainties regarding the approval process and timeline [2].

千金药业（600479）(600479.SH)发布公告，公司拟通过发行股份及支付现金方式购买湖南千金湘江药 业股份有限公司28.92%的股权及湖南千金协力药业有限公司68.00%的股权。根据上海证券交易所并购 重组审核委员会公告的《上海证券交易所并购重组审核委员会2025年第12次审议会议公告》，上交所并 购重组审核委员会定于2025年8月18日召开2025年第12次并购重组审核委员会审议会议，审核公司本次 交易的申请。 ...

格隆汇8月12日丨千金药业(600479.SH)公布，根据上海证券交易所（以下简称"上交所"）并购重组审核 委员会公告的《上海证券交易所并购重组审核委员会2025年第12次审议会议公告》，上交所并购重组审 核委员会定于2025年8月18日召开2025年第12次并购重组审核委员会审议会议，审核公司本次交易的申 请。 ...

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) plans to acquire 28.92% equity of Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. and 68.00% equity of Hunan Qianjin Xieli Pharmaceutical Co., Ltd. through a combination of share issuance and cash payment [1] Group 1 - The acquisition is subject to review by the Shanghai Stock Exchange's M&A Reorganization Review Committee, which is scheduled to meet on August 18, 2025, to assess the company's application for this transaction [1]